ArticleBMC gastroenterology2025
Non-linear relationship between the hepatic steatosis index and glycemic progression: evidence from a large-scale retrospective cohort study in a Chinese population.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe hepatic steatosis index (HSI) is a validated tool for assessing hepatic steatosis. While previous investigations have explored the link between HSI and prediabetes and diabetes, the connection between HSI and glycemic progression is still being explored. This research seeks to clarify the association between HSI and glycemic progression risk among a Chinese demographic.
methodsThe research encompassed a group of 76,314 Chinese adults from the Rich Healthcare Group who were free of prediabetes at the outset. Cox proportional hazard models were utilized to investigate the connection between the HSI and glycemic progression. Additionally, cubic spline function and smooth curve fitting in the Cox regression framework were applied to identify potential non-linear associations between HSI and glycemic progression.
resultsMultivariable analysis demonstrated that with each incremental unit in the HSI, there was a corresponding 5.4% rise in the risk of glycemic progression among females (HR: 1.054, 95%CI: 1.038-1.071) and a 3.7% increase in males (HR: 1.037, 95% CI: 1.028-1.046). Both genders exhibited a non-linear connection between HSI and the risk of glycemic progression. The inflection points for HSI were determined to be 36.595 for females and 34.328 for males. Within the female population, a significant positive association with glycemic progression risk was noted when HSI levels were below 36.595 (approximately 8.0% increased risk per unit) (HR: 1.080, 95%CI: 1.061-1.099, P < 0.0001), whereas this correlation was not statistically significant at HSI levels exceeding 36.595 (HR: 0.988, 95%CI: 0.960-1.016, P = 0.4010). In the male population, hazard ratios were 1.026 (95%CI: 1.013-1.038) (approximately 2.6% increased risk per unit) below the inflection point and 1.045 (95%CI: 1.034-1.056) (approximately 4.5% increased risk per unit) above it.
conclusionElevated HSI demonstrated a positive, non-linear correlation with the risk of glycemic progression, suggesting that maintaining lower HSI levels may mitigate the risk of developing glycemic progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.